Showing results (281-290 of 443) with videos related to
Sort By:
Pageof 45
Molecular and Cellular Biology|April 1, 1996
Raf, but not MEK or ERK, is sufficient for differentiation of hippocampal neuronal cellsW L Kuo, M Abe, J Rhee, et al.Breast Cancer Research and Treatment|June 15, 2014
Effect of multifocality and multicentricity on outcome in early stage breast cancer: a systematic review and meta-analysisFrancisco E Vera-Badillo, Marc Napoleone, Alberto Ocana, et al.Cancers|November 25, 2023
An Innovative Non-Linear Prediction Model for Clinical Benefit in Women with Newly Diagnosed Breast Cancer Using Baseline FDG-PET/CT and Clinical DataKen Kudura, Nando Ritz, Arnoud J Templeton, et al.Journal of the National Comprehensive Cancer Network : JNCCN|September 24, 2021
Associations With Definitive Outcomes and Clinical Benefit of Cancer Drugs at the Time of Marketing Approval and in the Postmarketing PeriodAida Bujosa, Consolación Moltó, Thomas J Hwang, et al.AIDS and Behavior|December 8, 2018
Predictors of Daily Adherence to HIV Pre-exposure Prophylaxis in Gay/Bisexual Men in the PRELUDE Demonstration ProjectStefanie J Vaccher, Mark A Marzinke, David J Templeton, et al.Journal of the National Cancer Institute|December 16, 2017
Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug AdministrationAriadna Tibau, Consolación Molto, Alberto Ocana, et al.Swiss Medical Weekly|January 30, 2018
Vitamin D levels in Swiss breast cancer survivorsMichael Baumann, Sergio Ulhoa Dani, Daniel Dietrich, et al.Genome Research|September 3, 2004
Comparative analysis of apicomplexa and genomic diversity in eukaryotesThomas J Templeton, Lakshminarayan M Iyer, Vivek Anantharaman, et al.Plos One|May 6, 2016
Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-RegressionArnoud J Templeton, Laura Diez Gonzalez, Francisco E Vera-Badillo, et al.Journal of Neuro-Oncology|January 29, 2014
Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progressionMairéad G McNamara, Zarnie Lwin, Haiyan Jiang, et al.Pageof 45